Efficacy of vedolizumab and ustekinumab in pediatric‐onset inflammatory bowel disease: A real‐world multicenter study
Authors:
- 16 October 2024
- journal article
- research article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 80 (1) , 113-123
Abstract
Objectives: Vedolizumab and ustekinumab are effective in inducing and maintaining corticosteroid‐free clinical remission (CFR) in adult patients with inflammatory bowel disease (IBD). This study describes the efficacy and safety of vedolizumab and ustekinumab in pediatric IBD.Methods: All patients ≤18 years of age with Crohn's disease (CD) or ulcerative colitis (UC) treated with vedolizumab or ustekinumab in three centers in Northern France were followed retrospectively. The primary outcome was CFR at Week 14 (W14).Results: Twenty‐five patients (9 CD, 16 UC) and 33 patients (28 CD, 5 UC) were started on vedolizumab and ustekinumab respectively between 2016 and 2021. All were previously treated with antitumor necrosis factor (TNF). The median time from diagnosis to treatment initiation was 21.0 (12.0–44.0) and 42.0 (22.0–73.5) months for vedolizumab and ustekinumab, respectively. Among vedolizumab‐treated patients, 36% were in CFR at W14, including 22% in CD and 44% in UC. At W52, 56% were in CFR, including 33% in CD and 69% in UC. Among ustekinumab‐treated patients, 49% were in CFR at W14, including 54% in CD and 20% in UC. At W52, 55% were in CFR, including 57% in CD and 40% in UC. There was a significant increase in median growth velocity between W0 and W52 of +2 SD in vedolizumab‐treated patients (p = 0.0002). Four adverse events were reported during vedolizumab treatment, none for ustekinumab‐treated patients.Conclusions: Vedolizumab and ustekinumab appear to be effective in inducing and maintaining CFR in pediatric‐onset IBD. Randomized controlled trials are needed to confirm these results.Keywords
This publication has 40 references indexed in Scilit:
- Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-center Retrospective Study from the Pediatric IBD Porto Group of ESPGHANPediatric Drugs, 2024
- STEP-CD study: ustekinumab use in paediatric Crohn’s disease—a multicentre retrospective study from paediatric IBD Porto group of ESPGHANEuropean Journal of Pediatrics, 2024
- Real‐world effectiveness of ustekinumab and vedolizumab in TNF‐exposed pediatric patients with ulcerative colitisJournal of Pediatric Gastroenterology and Nutrition, 2024
- Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish studyEuropean Journal of Pediatrics, 2021
- Long-term outcome of pediatric-onset Crohn’s disease: A population-based cohort studyDigestive and Liver Disease, 2019
- Biologics Delay Progression of Crohn’s Disease, but Not Early Surgery, in ChildrenClinical Gastroenterology and Hepatology, 2018
- Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 MonthsClinical Gastroenterology and Hepatology, 2017
- Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative ColitisClinical Gastroenterology and Hepatology, 2012
- Pediatric modification of the Montreal classification for inflammatory bowel diseaseInflammatory Bowel Diseases, 2011
- Natural history of Crohnʼs diseaseInflammatory Bowel Diseases, 2010